UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 23, 2019

Arvinas, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-38672**	**47-2566120**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

5 Science Park **395 Winchester Ave.** **New Haven, Connecticut**	**06511**
(Address of principal executive offices)	**(Zip Code)**

Registrant's telephone number, including area code: (203) 535-1456

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	**ARVN**	**The Nasdaq Stock Market LLC**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 8.01 Other Events

On October 23, 2019, Arvinas, Inc. (the "Company") issued a press release announcing a platform update that includes initial safety, tolerability and pharmacokinetic data from its ongoing Phase 1 clinical trial of ARV-110 in patients with metastatic castration-resistant prostate cancer (mCRPC) and its ongoing Phase 1 clinical trial of ARV-471 in patients with locally advanced or metastatic estrogen receptor positive (ER+) / human epidermal growth factor receptor-2 negative (HER2-) breast cancer. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The Company will present the initial data from the Phase 1 clinical trials at the 2nd Targeted Protein Degradation Summit on October 23, 2019. The presentation containing the initial data from the Phase 1 clinical trials is attached hereto as Exhibit 99.2 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1	Press Release, dated October 23, 2019.
99.2	Company presentation, dated October 23, 2019.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARVINAS, INC.

Date: October 23, 2019

By: /s/ Sean Cassidy
Sean Cassidy
Chief Financial Officer

Exhibit 99.1

Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders

-Data from initial cohorts suggest that Arvinas' PROTAC® platform has the potential to create safe and well-tolerated orally bioavailable drugs for the treatment of certain cancers

-Conference call to be held at 8:30 AM ET today

NEW HAVEN, CT, October 23, 2019 – Arvinas, Inc., (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced a platform data update that includes initial safety, tolerability, and pharmacokinetic data from the company's ongoing Phase 1 clinical trials of ARV-110 and ARV-471. The data, which show dose-proportional exposures of ARV-110 and that both ARV-110 and ARV-471 have been well tolerated, will be presented by Ian Taylor, Ph.D., Chief Scientific Officer at Arvinas, at the 2nd Targeted Protein Degradation Summit in Boston, MA. Dr. Taylor's presentation will be available on Arvinas' website this morning.

"This is the first look at clinical data from our PROTAC® platform and is an exciting milestone for both Arvinas and for the field of targeted protein degradation. We are seeing a favorable overall safety profile for both clinical programs to date, and dose-proportional exposures of ARV-110," said John Houston, Ph.D., Chief Executive Officer at Arvinas. "We are encouraged by these initial results as we work to create well tolerated therapies to treat serious diseases."

Phase 1 Study Designs and Clinical Data

Both ARV-110 and ARV-471 are being evaluated in Phase 1, open-label, dose-escalation clinical trials designed to assess safety, tolerability, and pharmacokinetics (PK).

The ARV-110 clinical trial is of 28 to 36 patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies. The ARV-471 clinical trial is of 24 to 36 patients with estrogen receptor positive (ER+) / human epidermal growth factor receptor-2 negative (HER2-) locally advanced or metastatic breast cancer who have received prior hormonal therapy and chemotherapy.

Both ARV-110 and ARV-471 are oral therapies dosed once per day.

The presentation today will show that Arvinas' PROTAC® protein degraders have been well tolerated by patients at the doses tested to date. The initial data for ARV-110 are from the first three dose-escalation cohorts (35 mg, 3 patients; 70 mg, 4 patients; and 140 mg, 3 patients), while the initial data presented for ARV-471 are from three patients enrolled in the first dose cohort (30 mg). Both ARV-110 (35, 70, and 140 mg) and ARV-471 (30 mg) were well tolerated, with no dose-limiting toxicities (DLTs) and no grade 2, 3, or 4 related adverse events observed.

The presentation today will also show dose proportionality for ARV-110 and that exposures of both ARV-110 and ARV-471 have reached levels associated with tumor growth inhibition in preclinical studies. For both programs and at each dose level tested to date, PK data were evaluated at days 1 and 15 following initial dosing. The third (140 mg) cohort of ARV-110 and the first (30 mg) cohort of ARV-471 reached average plasma exposures and average maximum concentrations that were above the lower ends of the ranges that were associated with tumor growth inhibition in preclinical studies. In addition, increases in exposure and average maximum concentration of ARV-110 were dose-proportional across all three doses tested to date.

For the next cohorts of each of ARV-110 and ARV-471, the dose is being increased by 100% (to 280 mg for ARV-110, and to 60 mg for ARV-471). Aside from continuing to investigate safety and PK, the Phase 1 clinical trial of ARV-110 will also evaluate biochemical and clinical activity by assessing prostate specific antigen (PSA) levels and RECIST response in patients with baseline measurable disease, androgen receptor (AR) degradation, and other exploratory biomarkers. The Phase 1 clinical trial of ARV-471 will continue to evaluate safety and PK, as well as evaluate estrogen receptor (ER) degradation, RECIST response in patients with baseline measurable disease, and other exploratory biomarkers.

Arvinas expects to next share clinical data from the Phase 1 dose escalation trial of ARV-110 in the first half of 2020 and from the Phase 1 dose escalation trial of ARV-471 in the second half of 2020.

Conference Call:

The company will host a conference call and webcast at 8:30 AM ET today to discuss these initial data. Participants are invited to listen by dialing (844) 467-7654 (domestic) or (602) 563-8497 (international) five minutes prior to the start of the call and providing the passcode access code 9096099. A listen-only webcast of the conference call can also be accessed through the “Investors” tab on the Arvinas website, www.arvinas.com, and a replay will be available for six weeks following the call.

About Arvinas:

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company has two clinical-stage programs: ARV-110 for the treatment of patients with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with ER+/HER2- locally advanced or metastatic breast cancer. For more information, visit www.arvinas.com.

About ARV-110

ARV-110 is an orally-bioavailable PROTAC® protein degrader designed to selectively target and degrade the androgen receptor (AR). ARV-110 is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer (mCRPC). Arvinas' Phase 1 trial of ARV-110 will assess its safety, tolerability, and pharmacokinetics, and will also include measures of anti-tumor activity and pharmacodynamic readouts as secondary endpoints.

ARV-110 has demonstrated activity in preclinical models of AR mutation or overexpression, both common mechanisms of resistance to currently available AR-targeted therapies.

About ARV-471

ARV-471 is a PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of women with metastatic breast cancer. Arvinas' Phase 1 trial of ARV-471 will assess its safety, tolerability, and pharmacokinetics, and will also include measures of anti-tumor activity and pharmacodynamic readouts as secondary endpoints.

In preclinical studies, ARV-471 demonstrated near-complete ER degradation in tumor cells, induced robust tumor shrinkage when dosed as a single agent in multiple ER-driven xenograft models, and showed superior anti-tumor activity as a single agent and in combination with a CDK4/6 inhibitor when compared to a standard of care agent, fulvestrant (as a single agent and in combination with a CDK4/6 inhibitor).

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the development and regulatory status of our product candidates, such as statements with respect to our lead product candidates, ARV-110 and ARV-471, and the timing of clinical trials and data from those trials for our product candidates, and our discovery programs that may lead to our development of additional product candidates, the potential utility of our technology and advantages and therapeutic potential of our product candidates, and the sufficiency of our cash resources. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to: whether we will be able to successfully conduct Phase 1 clinical trials for ARV-110 and ARV-471, complete other clinical trials for our product candidates, and receive results from our clinical trials, on our expected timelines, or at all, whether our cash resources will be sufficient to fund our foreseeable and unforeseeable operating expenses and capital expenditure requirements on our expected timeline and other important factors discussed in the "Risk Factors" sections contained in our quarterly and annual reports on file with the Securities and Exchange Commission. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this release.

Contacts for Arvinas

Investor Relations

Will O'Connor, Stern Investor Relations
ir@arvinas.com

Media

Cory Tromblee, ScientPR
pr@arvinas.com

Exhibit 99.2

ARVINAS
The PROTAC® Company

Moving PROTAC® Protein Degraders from the Laboratory to the Clinic

IAN TAYLOR, PHD

2nd Annual Targeted Protein Degradation Summit

OCTOBER 2019

Safe Harbor and Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development and regulatory status of our product candidates, such as statements with respect to our lead product candidates, ARV-110 and ARV-471, and the timing of clinical trials and data from those trials for our product candidates, and our discovery programs that may lead to our development of additional product candidates, the potential utility of our technology and therapeutic potential of our product candidates, the potential commercialization of any of our product candidates, and the sufficiency of our cash resources. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to: whether we will be able to successfully conduct Phase 1 clinical trials for ARV-110 and ARV-471, complete other clinical trials for our product candidates, and receive results from our clinical trials on our expected timelines, or at all, whether our cash resources will be sufficient to fund our foreseeable and unforeseeable operating expenses and capital expenditure requirements on our expected timeline and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, discussed in the "Risk Factors" section of the Company's quarterly and annual reports on file with the Securities and Exchange Commission. The forward-looking statements contained in this presentation reflect our current views as of the date of this presentation with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law.

ARVINAS

Arvinas: Company Overview

HISTORY

- Founded July 2013; New Haven, CT
- ~125 employees
- September 2018 IPO

PIPELINE

- **ARV-110** - Metastatic castration-resistant prostate cancer; **Phase 1 initiated 1Q19**, and received "Fast Track" designation from FDA in May 2019
- **ARV-471** - Estrogen receptor-positive / HER2-negative locally advanced or metastatic breast cancer; **Phase 1 initiated 3Q19**
- Brain-penetrant PROTAC® programs targeting tauopathies and α-synucleinopathies

COLLABORATORS

- Exclusive worldwide license to PROTAC® degrader technology with Yale University
- Strategic, discovery-stage partnerships with Pfizer, Genentech and Bayer
- Partnerships across broad set of therapeutic areas and a JV for agricultural applications

OUTSTANDING TEAM

- Strong leadership team with unparalleled protein degrader development experience
- World-class board and advisors, including scientific founder Craig Crews (Yale)

ARVINAS

High Potential PROTAC® Pipeline, Focused on Cancer and Neurology[1]

1 Pipeline as of October 23, 2019

2 PSP, progressive supranuclear palsy

3 MSA, multiple systems atrophy

ARVINAS

The "Tenets of PROTAC® Degraders"

Areas where the PROTAC® mechanism of action may be particularly well-suited



ARVINAS

Two Big Questions of the PROTAC® Platform As It Moves From Laboratory to the Clinic



ARVINAS


Asking the Two Big Questions of
ARV-110: Androgen Receptor PROTAC®
ARVINAS

ARV-110: AR Degrader for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)[1]

Androgen Receptor (AR) Activity Drives Prostate Cancer

- Current agents work by decreasing androgen levels (abiraterone) or blocking androgen binding to AR (enzalutamide)
- **15-25%** of patients never respond to abiraterone or enzalutamide (**intrinsic resistance**)
- **Resistance mechanisms** to abiraterone and enzalutamide include:
  - **AR gene amplification** (40-60% of patients)
  - **AR gene enhancer amplification** (>70% of patients)
  - **AR point mutations** (~15% of patients)
  - **Intra-tumoral androgen production**

PROTAC® Degrader ARV-110

- Highly selective degrader of AR; DC_{50} = 1 nM
- In preclinical models, overcomes resistance mechanisms to enzalutamide and abiraterone
- Not brain penetrant
- First-in-class AR degrader being tested in men with metastatic castration-resistant prostate cancer who have progressed on standards of care (enzalutamide, abiraterone)
- **Phase 1 clinical trial initiated 1Q19**
- **Received FDA "Fast Track" designation in May 2019**



1. According to the American Cancer Society, prostate cancer is the second leading cause of cancer death in men in the U.S. (~174k diagnosed/yr1); 35-45k new incidences of mCRPC in the U.S. each year

ARVINAS

ARV-110 Potently and Rapidly Degrades AR and Inhibits Proliferation Better than Enzalutamide in Preclinical Models

In vitro studies

- ARV-110 degraded 95% to 98% of AR in multiple cell lines typically used in prostate cancer research, including VCaP cells
  - DC_{50} in VCaP = 1 nM
  - Near-maximal degradation within 4 hours of administration
  - ARV-110 inhibits VCaP proliferation ~60x more potently than enzalutamide



VCaP Cells:







ARVINAS

ARV-110 Inhibits AR-Dependent Tumor Growth in Xenograft Models with Oral, Daily Dosing



mpk = mg/kg







Dose po, qd	Mean AUC_{0-24} ng*hr/ml†	Mean C_{max} ng/ml‡
1 mpk	3628	224
3 mpk	8106	507

Values represent total drug concentrations

† AUC_{0-24} or Area Under the Curve is a measurement of total exposure from 0-24 hours after last dose

‡ C_{max} is a measurement of peak concentration

ARVINAS

ARV-110: GLP Toxicology Studies Supported Moving into Clinical Development

Design:

Animals dosed daily, orally for 28 days; 14-day recovery for high-dose animals

Dog Study:

- 3, 10, or 30 mpk;
- 30 mpk exceeded MTD;

  NOAEL = 10 mpk
- **DLT: Gastrointestinal alteration** (e.g., loose/discolored stools) at all dose levels, including with vehicle alone

  Dog is most sensitive species
- Reversible liver function enzyme elevation in some mid- and high-dose animals; considered non-adverse
- **Decreased prostate weights** in all male animals; believed attributable to ARV-110 pharmacology

Rat Study:

- Male animals, 20, 60, or 120 mpk per day; Female animals, 20, 40, or 80 mpk per day
- Overall, ARV-110 was well tolerated at all doses

  Exception: 80 mpk in females; decreased body weight and food consumption; **NOAEL = 40 mpk**

  All findings in male high-dose animals (liver hypertrophy, femur physis thickening) fully reversible; **NOAEL = 120 mpk**
- **Decreased prostate weights** noted in all male animals; believed attributable to ARV-110 pharmacology

MTD, maximum tolerated dose. NOAEL, no observed adverse effect level; mpk = mg/kg

ARVINAS

ARV-110: Phase 1 Study

First patient dosed March 2019

Design:

- "3 + 3" dose escalation; starting dose = 35 mg, orally, once daily (po, qd) with food
- Dose increases dependent on toxicities: range 25% (if 1 DLT in 6 pts) to 100% (≤Grade 1 Adverse Events)

Key Entry Criteria:

- Men with mCRPC
- At least two prior systemic therapies, at least one of which was abiraterone or enzalutamide
- Disease progression on most recent therapy
  - Rising PSA or 2+ new lesions upon bone scan

Key Objectives:

- Maximum Tolerated Dose/ Recommended Phase 2 Dose/ Safety
- Pharmacokinetics
- Anti-Tumor Activity (PSA, RECIST)
- Biomarkers

Biomarkers:

- AR degradation in circulating tumor cells (CTCs) and pre- vs post-treatment biopsies (when available)
- AR (and other) gene mutations, amplifications in circulating tumor DNA (ctDNA)
- AR-V7 in CTCs

PSA, Prostate specific antigen. RECIST, Response evaluation criteria in solid tumors

ARVINAS

ARV-110 Phase 1 Dose Escalation— Pharmacokinetics is Dose Proportional

Preclinical Efficacious Exposure Range

Dose (po, qd)	AUC_{0-24} (ng*hr/ml)	C_{max} (ng/ml)
1 mpk	3628	224
3 mpk	8106	507

Phase 1 Data

Dose po, qd	Day 1 AUC_{0-24} (ng*h/mL) Mean	Day 1 C_{max} (ng/ml) Mean	Day 15 AUC_{0-24} (ng*h/mL) Mean[a]	Day 15 C_{max} (ng/ml) Mean
35 mg	160.5	11.1	1701	83
70 mg	300	19.6	2538	141
140 mg	865	54	5023	353

[a] Day 15 AUCs calculated using imputed 24 hour values

- Accumulation occurs between Day 1 and Day 15

ARVINAS

ARV-110 Phase 1 Dose Escalation— Pharmacokinetics is Dose Proportional

Preclinical Efficacious Exposure Range

Dose (po, qd)	AUC_{0-24} (ng*hr/ml)	C_{max} (ng/ml)
1 mpk	3628	224
3 mpk	8106	507

Phase 1 Data

Dose po, qd	Day 1 AUC_{0-24} (ng*h/mL) Mean	Day 1 C_{max} (ng/ml) Mean	Day 15 AUC_{0-24} (ng*h/mL) Mean[a]	Day 15 C_{max} (ng/ml) Mean
35 mg	160.5	11.1	1701	83
70 mg	300	19.6	2538	141
140 mg	865	54	**5023**	**353**

[a] Day 15 AUCs calculated using imputed 24 hour values

- Accumulation occurs between Day 1 and Day 15
- Exposure at 140 mg has entered the preclinical efficacious range associated with tumor growth inhibition

ARVINAS

ARV-110 Phase 1 Dose Escalation— Pharmacokinetics is Dose Proportional





Orange lines represent AUC and C_{max} associated with tumor growth inhibition at 1 mpk and 3 mpk in preclinical models

Dose po, qd	Day 15 AUC_{0-24} (ng*h/mL) Mean[a]	Day 15 C_{max} (ng/ml) Mean
35 mg	1701	83
70 mg	2538	141
140 mg	5023	353

[a] Day 15 AUCs calculated using imputed 24 hour values

ARVINAS

ARV-110 Phase 1 Dose Escalation—
Day 15 Pharmacokinetics



T_{max}† = 4 - 8 hours

$t_{1/2}$‡ = estimated 3 - 7 days

† Time of to reach maximum concentration (Cmax)

‡ Effective half-life: rate of accumulation or elimination of a pharmacologic substance

Cohort 3 (140 mg)

Cohort 2 (70 mg)

Cohort 1 (35 mg)

24 hour values are imputed from time zero

ARVINAS

ARV-110 Phase 1 Dose Escalation Safety/Tolerability: Overall Favorable Profile Observed to Date

- Three cohorts through 28 day dose limiting toxicity evaluation period; fourth cohort enrolling

Dose Level[a]	N	Key Safety Findings
35 mg	3	• No Dose Limiting Toxicities (DLTs) • No Treatment Related Adverse Events (AEs)
70 mg	4	• No DLTs • No Grade 2/3/4 Treatment Related AEs
140 mg[b]	3[c]	• No DLTs • No Grade 2/3/4 Treatment Related AEs
280 mg	3	• TBD

[a] Orally, once daily

[b] Data not yet 100% source data verified

[c] Not including 1 non-evaluable patient (discontinued on day 1; patient's condition had worsened in the interval from screening to the morning of treatment initiation consistent with rapid progression of his cancer.)

ARVINAS

First-in-Human Androgen Receptor PROTAC®
ARV-110 Proceeding Through Dose Escalation

- 10 patients with mCRPC treated across three dose levels
- At doses thus far tested, ARV-110 demonstrating an acceptable safety profile
- Pharmacokinetics show dose-proportional increase in exposure
- Dose escalation continues into higher dose level(s)
- Topline data including PSA and RECIST responses from completed dose escalation – and pharmacodynamic/molecular data--planned in 1st half 2020 at major medical conference

ARVINAS


Two Big Questions, Asked a Second Time
ARV-471: Estrogen Receptor PROTAC®
ARVINAS

ARV-471: ER Degrader for Patients with Locally Advanced or Metastatic Breast Cancer

Breast cancer is the second most common cancer in women[1]

- ~268,000 women are expected to be diagnosed with invasive breast cancer in the US in 2019[1]
- Metastatic breast cancer accounts for ~6% of newly diagnosed cases[2]
- 80% of newly diagnosed breast cancers are estrogen receptor (ER) positive[3]
- Fulvestrant has validated the relevance of ER degradation in breast cancer
- After 6 months of fulvestrant treatment, up to 50% of ER baseline levels remain[4]

PROTAC® Degrader ARV-471

- ARV-471 is a potent degrader (DC_{50} = 1.8 nM) of the estrogen receptor, which is in development for the treatment of patients with ER+ locally advanced or metastatic breast cancer
- **Phase 1 clinical trial initiated 3Q2019**
- After Phase 1 dose escalation, a Phase 1b trial in combination with CDK4/6 inhibitor is planned

1 American Cancer Society;
2 Malmgren, J.A., Breast Cancer Res Treat (2018) 167:579–590;
3 National Cancer Institute, Hormone Therapy for Breast Cancer;
4 Gutteridge et. Al., Breast Cancer Res Treat 2004;**88** suppl 1:S177

ARVINAS

Orally Dosed ARV-471 Shrinks Tumors and Robustly Degrades ER in MCF7 Xenografts



Dose po, qd	Mean AUC_{0-24} ng*hr/ml	Mean C_{max} ng/ml
3 mpk	658	84
10 mpk	2538	312
30 mpk[a]	5717	962

[a] Single dose

Values represent total drug concentrations

WESTERN BLOT PD (18 hours post last dose)	% ER REDUCTION
3 mpk	95
10 mpk	97
30 mpk	94



ARVINAS

ARV-471: GLP Toxicology Studies Supported Moving into Clinical Development

Design:
Animals dosed once daily, orally, for 28 days; 28-day recovery period for high-dose animals.

Dog Study:

- Doses of 15, 45, or 90 mpk administered to all animals; **NOAEL = 90 mpk**

Rat Study:

- Doses of 3, 10, 30 or 100 mpk administered to all animals; **NOAEL = 100 mpk**

The studies have shown **no clinical signs of toxicity** following daily oral doses of ARV-471 up to 100 mg/kg/day in rats and 90 mg/kg/day in dogs, **nor effects on overall animal health and well-being**.

NOAEL, no observed adverse effect level

ARVINAS

ARV-471: Phase 1 Study

First patient dosed August 2019

Design:

- "3 + 3" dose escalation; starting dose = 30 mg orally, once daily (po, qd) with food
- Dose increases dependent on toxicities: range 25% (if 1 DLT in 6 pts) to 100% (≤Grade 1 Adverse Events)

Key Entry Criteria:

- ER+/HER2- advanced breast cancer
- At least two prior endocrine therapies in any setting, and a CDK4/6 inhibitor
- Up to three prior cytotoxic chemotherapy regimens

Key Objectives:

- Maximum Tolerated Dose/ Recommended Phase 2 Dose/Safety
- Pharmacokinetics
- Anti-tumor activity (RECIST, CBR)
- Biomarkers

Biomarkers:

- ER gene (ESR1) mutational status in ctDNA and/or tumor tissue
- ER, Progesterone Receptor and Ki-67 levels in pre- and post-treatment tumor biopsies in patients with accessible tumor tissue

CBR, clinical benefit rate

ARVINAS

ARV-471 Phase 1 Dose Escalation— First Cohort Pharmacokinetics

Preclinical Efficacious Exposure Range

Dose (po, qd)	Mean AUC_{0-24} (ng*hr/ml)	Mean C_{max} (ng/ml)
3 mpk	658	84
10 mpk	2538	312
30 mpk	5717	962

Phase 1 Data

Dose po, qd	Day 1 AUC_{TAU} (ng*h/mL) Mean	Day 1 C_{max} (ng/ml) Mean	Day 15 AUC_{TAU} (ng*h/mL) Mean[a]	Day 15 C_{max} (ng/ml) Mean
30 mg	1690	109	**4100**	**224**

[a] Day 15 AUCs calculated using imputed 24 hour values

- Accumulation occurs between Day 1 and Day 15
- Exposure at 30 mg has entered the preclinical efficacious range associated with tumor growth inhibition

ARVINAS

ARV-471 Phase 1 Dose Escalation—
First Cohort Pharmacokinetics



Day 15 24 hour value is imputed from time zero

T_{max} = 4 hours

$t_{1/2}$ = estimated to be ~24 hours

ARVINAS

ARV-471 Phase 1 Dose Escalation—Safety/Tolerability

- First cohort through 28 day dose limiting toxicity evaluation period; second cohort enrolling

Dose Level[a]	N	Key Safety Findings
30 mg[b]	3	• No DLTs • No Treatment Related AEs
60 mg	3	• TBD

[a] Orally, once daily

[b] Data not yet 100% source verified

- Trial update planned in 2nd half 2020

ARVINAS

Two Big Questions of the PROTAC® Platform

ARVINAS

Two Big Questions of the PROTAC® Platform



Today:

Favorable Initial Clinical Data from PROTAC® Platform:

- Two Different PROTAC® Degraders
- Two Different Cancer Indications
- Two Different Patient Populations

ARVINAS

The Next Big Question:
Will a PROTAC® Demonstrate Efficacy in the Clinic?

Planned Milestone Updates

- 1H20: Topline Data on Completed ARV-110 Phase 1 Dose Escalation
- 2H20: ARV-471 Phase 1 Update

ARVINAS


The Patients, Their Families and Caregivers
Investigators and Clinical Trial Site Staff
Thank You
ARVINAS

And All Arvinas Colleagues!

ARVINAS